RESUMO
BACKGROUND: Cervical thoracic duct cysts are a rare anomaly. OBJECTIVE: To report a case of cervical thoracic duct cyst, and perform a literature review. CLINICAL CASE: A 78-year-old female, with a one-year history of a left-sided asymptomatic supraclavicular cystic mass. Computerized tomography revealed a cystic mass 42mm in diameter. We performed a fine needle aspiration puncture, obtaining a thick, milky, whitish liquid. The patient underwent surgery; finding a left-sided supraclavicular cystic mass, with some lymph vessels heading towards the jugulo subclavian venous junction. We performed a ligation of these lymph vessels and resection of the mass. The histopathologic study confirmed the diagnosis of thoracic duct cyst. CONCLUSION: Diagnosis of cervical thoracic duct cyst should be suspected with a cystic lesion in the left supraclavicular region, which when perforated exudes a very distinctive thick milky, whitish liquid with a high content of lymphocytes and triglycerides. Treatment should be complete removal with ligation of the lymphatic afferent vessels.
Assuntos
Cisto Mediastínico/cirurgia , Ducto Torácico/cirurgia , Idoso , Biópsia por Agulha Fina , Feminino , Humanos , Ligadura , Vasos Linfáticos/cirurgia , Cisto Mediastínico/diagnóstico por imagem , Cisto Mediastínico/patologia , Ducto Torácico/diagnóstico por imagem , Ducto Torácico/patologia , Tomografia Computadorizada por Raios XRESUMO
No disponible
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Leiomioma/cirurgia , Leiomioma , Neoplasias Esofágicas/cirurgia , Neoplasias Esofágicas , Tomografia por Emissão de Pósitrons/métodos , Tomografia por Emissão de Pósitrons , Fluordesoxiglucose F18/análise , Laparotomia/métodos , Laparotomia , Diagnóstico Diferencial , Tumores do Estroma Gastrointestinal/patologia , Tumores do Estroma Gastrointestinal/cirurgia , Tumores do Estroma GastrointestinalAssuntos
Neoplasias Esofágicas/diagnóstico por imagem , Fluordesoxiglucose F18 , Leiomioma/diagnóstico por imagem , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Compostos Radiofarmacêuticos , Neoplasias Esofágicas/metabolismo , Feminino , Fluordesoxiglucose F18/farmacocinética , Humanos , Leiomioma/metabolismo , Pessoa de Meia-Idade , Compostos Radiofarmacêuticos/farmacocinética , Tomografia Computadorizada por Raios XRESUMO
No disponible
Assuntos
Humanos , Feminino , Idoso , Hemangioma/diagnóstico , Neoplasias Esofágicas/diagnóstico , Diagnóstico Diferencial , Leiomioma/diagnóstico , Tumores do Estroma Gastrointestinal/diagnósticoRESUMO
High-risk human papillomavirus (HPV) DNA detection provides high sensitivity but low specificity for moderate-grade cervical intraepithelial neoplasia or worse histological identification. A prospective study evaluated mRNA testing efficacy for predicting this histological diagnosis in case of HPV 16 and/or 18 DNA detection. A total of 165 endocervical samples harboring HPV 16 and/or 18 DNA were tested with NucliSENS-EasyQ® HPV E6/E7-mRNA-assay (Biomerieux, Marcy l´Etoile, France). Women with cytological alterations were referred to colposcopy (n = 111). Moderate-grade cervical intraepithelial neoplasia or worse was diagnosed in 25.8% of women presenting atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions and in 89.8% of women with high-grade squamous intraepithelial lesions. mRNA sensitivity was 81.3% and 84.1%, respectively. Specificity was 52.2%, and 80.0%, respectively. Negative predictive value (NPV) was 88.9% in undetermined or low-grade squamous lesions. Positive predictive value (PPV) was 97.4% in high-grade squamous lesions. mRNA reduced colposcopies by 44.3% in undetermined or low-grade squamous lesions. Direct treatment of mRNA-positive cases reduced 77.5% of colposcopies in high-grade squamous lesions. Women without cytological alterations were followed for 18 months (n = 35), and moderate-grade cervical intraepithelial neoplasia or worse was diagnosed in 34.3%; mRNA sensitivity and specificity were 83.3% and 86.9%, respectively. PPV and NPV were 76.9% and 90.9%, respectively for predicting moderate-grade cervical intraepithelial neoplasia or worse in 18 months. mRNA reduced the number of visits for follow-up in 62.2%. In conclusion, NucliSENS-EasyQ® HPV E6/E7-mRNA-assay (Biomerieux) can serve as a triage test in case of HPV 16 and/or 18 DNA detection.
Assuntos
Papillomavirus Humano 16/genética , Papillomavirus Humano 18/genética , Infecções por Papillomavirus/diagnóstico , RNA Mensageiro/genética , RNA Viral/genética , Displasia do Colo do Útero/diagnóstico , Neoplasias do Colo do Útero/diagnóstico , Adolescente , Adulto , Idoso , Colo do Útero/patologia , Colo do Útero/virologia , Colposcopia , Testes Diagnósticos de Rotina , Feminino , Papillomavirus Humano 16/isolamento & purificação , Papillomavirus Humano 18/isolamento & purificação , Humanos , Pessoa de Meia-Idade , Proteínas Oncogênicas Virais/análise , Proteínas Oncogênicas Virais/genética , Infecções por Papillomavirus/patologia , Infecções por Papillomavirus/virologia , Gravidez , Estudos Prospectivos , RNA Mensageiro/análise , RNA Viral/análise , Sensibilidade e Especificidade , Triagem , Neoplasias do Colo do Útero/patologia , Neoplasias do Colo do Útero/virologia , Displasia do Colo do Útero/patologia , Displasia do Colo do Útero/virologiaRESUMO
No disponible
Assuntos
Humanos , Leiomioma/cirurgia , Neoplasias Esofágicas/cirurgia , Procedimentos Cirúrgicos Minimamente Invasivos/métodos , Toracoscopia/métodos , Laparoscopia/métodosAssuntos
Neoplasias Esofágicas/cirurgia , Laparoscopia , Leiomioma/cirurgia , Toracoscopia , HumanosRESUMO
No disponible
Assuntos
Humanos , Masculino , Feminino , Transplante , Síndrome de Budd-Chiari/complicações , Síndrome de Budd-Chiari/diagnóstico por imagem , Hepatomegalia/diagnóstico por imagem , Sobrevivência de Enxerto , Síndrome de Budd-Chiari/etiologia , Síndrome de Budd-Chiari/patologia , Estudos Retrospectivos , Diagnóstico Diferencial , Algoritmos , Trombose/tratamento farmacológico , Anticoagulantes/uso terapêuticoRESUMO
OBJECTIVE: To evaluate the effect of treatment with murine recombinant interleukin-1 beta on inflammatory infiltrate and tissue damage after experimental endotoxic challenge. DESIGN: Randomized, controlled study. SETTING: Experimental Unit, Virgen de las Nieves University Hospital. SUBJECTS: Seventy-two female CBA/H mice, 20-21 g, supplied by the animal center of the Experimental Unit. INTERVENTION: The mice were randomized into three groups of 24. Group 1 (sham) received two intraperitoneal doses of 0.1 mL of phosphate-buffered saline; group 2 (lipopolysaccharide) was injected with 125 mg/kg lipopolysaccharide (Escherichia coli, intraperitoneally) 24 hrs after 0.1 mL of phosphate-buffered saline; group 3 was pretreated with 80 ng of recombinant interleukin-1 beta per mouse (intraperitoneally) 24 hrs before the endotoxic challenge. MEASUREMENTS AND MAIN RESULTS: At 1, 2, 4, and 24 hrs after the endotoxic challenge, we studied inflammatory infiltrate and tissue damage in lung, liver, and intestine by determining myeloperoxidase and malondialdehyde tissue concentrations. When we compared the pretreated group with the lipopolysaccharide group, myeloperoxidase concentrations decreased significantly in lung (p <.001) and liver (p <.001) at all study times, and in intestine (p <.001) at 2, 4, and 24 hrs; malondialdehyde concentrations significantly decreased in lung at 1 (p <.05), 2 (p <.01), and 24 (p <.001) hrs, in liver at 2 (p <.001), 4 (p <.01), and 24 (p <.001) hrs, and in intestine at 1 (p <.001), 2, 4 (p <.05), and 24 (p <.001) hrs. CONCLUSION: Pretreatment with recombinant interleukin-1 beta significantly reduces inflammatory infiltrate and tissue damage in mouse lung, liver, and intestine after an experimental endotoxic challenge.
